Tumor Registry of Lymphatic Neoplasia (TLN-Registry)
|Non-Hodgkin's Lymphoma (NHL) Chronic Lymphocytic Leukemia (CLL) Multiple Myeloma (MM)|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Malignant Lymphatic Systemic Diseases (Non-Hodgkin`s Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma) Requiring Therapy.|
- Documentation of anamnestic data and therapy sequences [ Time Frame: 5 years per patient ]
- Documentation of response rates and progression-free survival per therapy sequence, overall survival time and adverse reactions [ Time Frame: 5 years per patient ]
|Study Start Date:||April 2009|
|Estimated Study Completion Date:||December 2019|
|Estimated Primary Completion Date:||August 2019 (Final data collection date for primary outcome measure)|
The TLN is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of lymphatic neoplasms in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.
The impact of nutrition (LyNut) and physical activity (LyNut) on the course of the adjuvant disease will be examined in patients with indolent and aggressive Non-Hodgin Lymphoma, as well as long-term effects of systemic treatment (LyTox) and quality of life (LyLife) in patients with multiple myeloma.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00889798
|Study Chair:||Wolfgang Knauf, MD||Center for Haematology, Frankfurt, Germany|
|Study Chair:||Wolfang Abenhardt, MD||MVZ Onkologie im Elisenhof, München, Germany|